ロード中...
Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma
Sorafenib is the first-line medication for advanced hepatocellular carcinoma (HCC), but it can only extend limited survival. It is imperative to find a combination strategy to increase sorafenib efficacy. Artesunate is such a preferred candidate, because artesunate is clinically well-tolerated and m...
保存先:
| 出版年: | Acta Pharmacol Sin |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer Singapore
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8026986/ https://ncbi.nlm.nih.gov/pubmed/32699265 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41401-020-0478-3 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|